Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

News | Drug-Eluting Balloons

September 11, 2023 — The first patient has been enrolled in a UK study of large vessel de novo coronary artery disease t ...

Home September 11, 2023
Home
Annual Scientific Symposium will take place October 23-26 in San Francisco
Feature | TCT

September 6, 2023 — The Cardiovascular Research Foundation (CRF) has announced the TCT 2023 late-breaking clinical ...

Home September 06, 2023
Home
News | Antiplatelet and Anticoagulation Therapies

August 28, 2023 — Prasugrel monotherapy after percutaneous coronary intervention (PCI) with drug-eluting stents is not ...

Home August 28, 2023
Home
News | Drug-Eluting Balloons

July 14, 2023 — BIOTRONIK announced the one-year subgroup results from the investigator-initiated BIOPACT randomized ...

Home July 14, 2023
Home
News | Drug-Eluting Balloons

May 30, 2023 — Twelve-month results from the SELUTION SFA trial have been presented for the first time at the Japan  ...

Home May 30, 2023
Home
News | Drug-Eluting Balloons

May 12, 2023 — The US FDA has granted an Investigational Device Exemption (IDE) approval for Concept Medical Inc’s novel ...

Home May 12, 2023
Home
News | Drug-Eluting Balloons

May 4, 2023 — The first US patient has been enrolled in the SELUTION4SFA Sirolimus DEB study by Dr. Arthur Lee at the Ca ...

Home May 04, 2023
Home
News | Drug-Eluting Balloons

April 28, 2023 — Medtronic today shared additional 36-month data from the IN.PACT AV Access Study, as well as 48-month ...

Home April 28, 2023
Home
Feature | Cardiovascular Business | By Emily Gilbert and Kamran Zamanian, PhD

The European interventional cardiology device market is one of the larger markets in the global space. The market is ...

Home April 24, 2023
Home
News | Drug-Eluting Balloons

March 14, 2023 —MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coron ...

Home March 14, 2023
Home
News | Drug-Eluting Balloons

January 27, 2023 — The first US patient has been enrolled at Medstar Washington Hospital Center in the SELUTION4ISR ...

Home January 27, 2023
Home
Subscribe Now